Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO2006099591 - NANOPARTICULATE LEUKOTRIENE RECEPTOR ANTAGONIST/CORTICOSTEROID FORMULATIONS

Publication Number WO/2006/099591
Publication Date 21.09.2006
International Application No. PCT/US2006/009837
International Filing Date 16.03.2006
IPC
A61K 9/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
A61K 31/404 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
A61K 31/573 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
57substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
573substituted in position 21, e.g. cortisone, dexamethasone, prednisone
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
CPC
A61K 31/404
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
A61K 31/4188
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4188condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
A61K 31/573
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
57substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
573substituted in position 21, e.g. cortisone, dexamethasone, prednisone ; or aldosterone
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Applicants
  • ELAN PHARMA INTERNATIONAL LIMITED [IE]/[IE] (AllExceptUS)
  • LIVERSIDGE, Gary [US]/[US] (UsOnly)
  • JENKINS, Scott [US]/[US] (UsOnly)
  • WERTZ, Christian [US]/[US] (UsOnly)
  • BOSCH, H. [US]/[US] (UsOnly)
Inventors
  • LIVERSIDGE, Gary
  • JENKINS, Scott
  • WERTZ, Christian
  • BOSCH, H.
Agents
  • SIMKIN, Michele
Priority Data
60/662,33916.03.2005US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NANOPARTICULATE LEUKOTRIENE RECEPTOR ANTAGONIST/CORTICOSTEROID FORMULATIONS
(FR) FORMULATIONS NANOPARTICULAIRES D'UN ANTAGONISTE DU RECEPTEUR DE LEUKOTRIENE/D'UN CORTICOSTEROIDE
Abstract
(EN)
Nanoparticulate compositions comprising a corticosteroid and a leukotriene receptor antagonist are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining a leukotriene receptor antagonist with a corticosteroid in particle size ranges of less than 2000 n in a single formulation results in improved efficacy. In addition, patient compliance is enhanced since only one dosage form is needed. Furthermore, local administration of the leukotriene receptor antagonist results in less liver toxicity since the liver will be exposed to lower amounts of drug than happens following oral administration. The drug compositions according to the invention can be formulated into inhalation, nasal, or ocular formulations.
(FR)
L'invention porte sur des compositions nanoparticulaires contenant un corticostéroïde et un antagoniste du récepteur de leukotriène. Ces compositions sont utiles dans la prophylaxie et le traitement chronique d'asthme chez des adultes et des patients pédiatriques, ainsi que dans le soulagement de conjonctivites allergiques, de symptômes de rhinites allergiques saisonnières chez des adultes et des enfants. La combinaison d'un antagoniste du récepteur de leukotriène avec un corticostéroïde selon une granulométrie inférieure à 2000 nm dans une formulation unique permet d'obtenir une meilleure efficacité. De plus, la conformité au patient est améliorée puisqu'une seule forme de dosage est nécessaire. De plus, l'administration locale de l'antagoniste du récepteur de leukotriène permet de diminuer la toxicité du foie puisque le foie sera exposé à des quantités inférieures de médicaments suite à l'administration orale. Ces compositions de médicaments peuvent être formulées sous forme d'inhalation, de formulations nasales ou oculaires.
Other related publications
Latest bibliographic data on file with the International Bureau